Generation Y ��born roughly from 1977 to 1994 ��are more than 80 million strong and nearly 50 million of them plan to buy a new or used car in the next three years, according to Craig Griffi, Deloitte vice chairman and automotive practice leader
"There's been a lot of conjecture about whether Gen-Yers even like driving," Griffi said. But Deloitte found nearly two-thirds of Gen Y Americans "would indicate that they love their cars."
Nearly 700 Gen-Y-age Americans participated in Deloitte's survey, which encompassed more than 23,000 respondents across 19 countries. The company will release full results later this year, but it disclosed some findings earlier this week on a group that automakers have spent years trying to understand.
5 Best Oil Service Stocks To Watch For 2015: Network Engines Inc(NEI)
Network Engines, Inc. designs and manufactures application platforms and appliance solutions on which software applications are applied for enterprise and telephony information technology networks. The company?s application platforms are pre-configured server-based network infrastructure devices designed to deliver specific software application functionality, and enhance the integration, manageability, and security of that software application in an end user?s network. It also offers platform management software tools and support services related to solution design, systems integration, application management, global logistics, and support and maintenance programs. The company markets its application platform solutions and services to original equipment manufacturers and independent software vendors in the United States and internationally. Network Engines, Inc. was founded in 1989 and is headquartered in Canton, Massachusetts.
Advisors' Opinion:- [By CRWE]
NEI (Nasdaq:NEI), a leading provider of server-based application platforms, deployment solutions and lifecycle support services for software technology developers and OEMs worldwide, announced today that it has signed a definitive merger agreement with UNICOM Systems, Inc. (“UNICOM”) and a new UNICOM subsidiary under which UNICOM, a global information technology company and part of the UNICOM group of companies, will acquire NEI for $1.45 per common share in cash.
Best Healthcare Technology Companies To Invest In 2014: Gardner Denver Inc. (GDI)
Gardner Denver, Inc. designs, manufactures, and markets engineered industrial machinery and related parts and services primarily in North America, Europe, Asia, South America, Africa, and Australia. It operates in two segments, Industrial Products Group and Engineered Products Group. The Industrial Products Group segment offers rotary screw, reciprocating, and sliding vane air and gas compressors; positive displacement, centrifugal, and side channel blowers; and vacuum pumps for use in manufacturing, transportation and general industry, and original equipment manufacturer (OEM) and engineered system applications. This segment also markets and services complementary ancillary products. The Engineered Products Group segment designs, manufactures, markets, and services pumps, compressors, liquid ring vacuum pumps, reciprocating pumps, diaphragm vacuum pumps, water jetting systems, and related aftermarket parts used in oil and natural gas well drilling, servicing, and producti on, as well as in medical and laboratory, and industrial cleaning and maintenance. It also offers liquid ring pumps for various applications, such as water removal, distilling, reacting, flare gas recovery, efficiency improvement, lifting and handling, and filtering, principally in the pulp and paper, industrial manufacturing, petrochemical, and power industries. In addition, this segment designs, manufactures, markets, and services other fluid transfer components and equipment, including loading arms, swivel joints, storage tank equipment, dry- break couplers, and tank truck systems for the chemical, petroleum, and food industries. The company sells its products through independent distributors and sales representatives, as well as directly to OEMs, engineering firms, packagers, and end users. Gardner Denver, Inc. was founded in 1993 and is based in Wayne, Pennsylvania.
Advisors' Opinion:- [By Eric Volkman]
Gardner Denver (NYSE: GDI ) results for the company's Q1 have been unveiled. For the quarter, revenue was $514 million, a 15% drop from the $604 million in the same period the previous year. Net income saw a steeper decline over that time frame, by 17%, to $46 million ($0.93 per diluted share) from Q1 2012's $55 million ($1.08).
Best Healthcare Technology Companies To Invest In 2014: Digi International Inc.(DGII)
Digi International Inc. engages in the provision of machine to machine networking products and solutions to connect, monitor, and control of local or remote physical assets by electronic means. It offers a range of embedded products, including modules, single board computers, chips, satellite communication devices, and software and development tools; and non embedded products comprising cellular products, serial servers, console servers, universal serial bus connected products, serial cards, and wireless communication adaptors. The company also provides wireless product design and development services to provide wireless networking products. In addition, it offers iDigi, a cloud-based Internet platform to connect enterprise applications to remote electronic devices. The company sells its products through a network of distributors, systems integrators, and value added resellers for a range of businesses and institutions, as well as to original equipment manufacturers primar ily in North America, Europe, the Middle East, Africa, Asia, and Latin America. It has strategic alliances with VMware, Ember, Freescale, Qualcomm, Ericsson, Itron, AT&T, Sprint, Verizon, Bell Mobility, and Rogers. The company was founded in 1985 and is headquartered in Minnetonka, Minnesota.
Advisors' Opinion:- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Digi International (Nasdaq: DGII ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Digi International doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue decreased 5.8%, and inventory increased 3.2%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue shrank 1.7%, and inventory grew 3.2%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 2.6%, and inventory grew 1.7%. - [By John Kell]
Digi International Inc.'s(DGII) fiscal first quarter earnings fell, as high costs masked a slight rise in revenue. The wireless-product provider’s results were well-below the company’s previous guidance. Shares slumped 9.9% to $10.89 premarket.
- [By John Udovich]
Small cap machine-to-machine (M2M) stock Elecsys Corp (NASDAQ: ESYS) jumped 8.99% yesterday and is up 254% over the past year, meaning it might be time to take a closer look at the stock and its performance verses other small cap M2M stocks like Digi International Inc (NASDAQ: DGII), Numerex Corp (NASDAQ: NMRX) and Sierra Wireless, Inc (NASDAQ: SWIR). First of all though, I should mention that machine-to-machine (M2M) broadly refers to technologies that allow both wireless and wired systems to communicate with other devices of the same type and this can be through any type of technology ranging from instruments to networks to applications that create connections between devices.
Best Healthcare Technology Companies To Invest In 2014: ArthroCare Corporation(ARTC)
ArthroCare Corporation, a medical device company, develops, manufactures, and markets surgical products primarily based on its minimally invasive patented Coblation technology in the Americas and internationally. The company?s Sports Medicine business provides energy-based systems and fixation technologies used to treat soft tissue injuries in the shoulders, knees, and hips. It offers ArthroWands product line that features Coblation based specialized disposable energy-based surgical wands designed for single patient use to treat orthopedic conditions, including shoulder, knee, hip, foot, ankle, elbow, and wrist injuries; and Soft-Tissue Fixation products comprising a line of specialized implants and instruments, such as knotless and traditional anchors for rotator cuff and labrum repairs in shoulder; screws for ligament reconstruction in knee; a range of arthroscopic suture passers; and reusable hand-held instruments, procedural kits, and accessories. The company?s Ear N ose and Throat (ENT) business provides surgical products used to treat conditions performed by ENT healthcare professionals. It offers various products for general head, neck, and oral surgical procedures, including sinus surgery, snoring treatment, nasal turbinates reduction, and adenoid and tonsil removal. The company also provides surgical products for the treatment of spine related and other conditions. Its products include SpineWand devices used to treat soft tissue conditions in spine; Plasma Disc Decompression products for treating contained herniated discs; Cavity SpineWand that reduces the size of malignant lesions in the vertebrae of patients suffering from spinal compression fractures; and WoundWand for acute and chronic wound debridement, and wound cleansing. ArthroCare sells its products to surgeons and specialized medical professionals through sales representatives, and independent sales agents and distributors. The company was founded in 1993 and is headquarte red in Austin, Texas.
Advisors' Opinion:- [By Jake L'Ecuyer]
Top Headline
Smith & Nephew PLC (NYSE: SNN) announced its plans to buy ArthroCare (NASDAQ: ARTC) for $1.7 billion in cash. Smith & Nephew will pay $48.25 per share in cash to acquire ArthroCare, representing a 6.3% premium to ArthroCare's closing price on January 31.
Best Healthcare Technology Companies To Invest In 2014: Syngenta AG (SYNN)
Syngenta AG is a Switzerland-based company engaged in production of products for crop productivity. The Company's businesses include herbicides, insecticides and fungicides for crop protection, field crops, vegetables and flower seeds, seed care products and turf, garden, home care and public health products. The Company diversifies its operations into four geographical segments (Europe, Africa and Middle East; North America; Latin America and Asia Pacific), which represent the integrated Crop Protection and Seeds business areas, as well as a separate global segment Lawn and Garden. The Crop Protection business is active in herbicides, insecticides and fungicides manufacture. The Seeds business produces and sells seeds for growing corn, soybeans, sunflower, and sugar beet, among others. The Lawn and Garden business offers a range of products for use in the flower genetics, ornamentals, consumer lawn and garden, and Turf and landscape markets. Advisors' Opinion:- [By Sofia Horta e Costa]
Volvo AB (VOLVB) advanced the most in 10 months after the world�� second-largest truckmaker reported second-quarter earnings that beat forecasts. EasyJet climbed 3.7 percent after saying quarterly sales rose 11 percent on higher capacity utilization and revenue per seat. Syngenta (SYNN) AG fell 4 percent after posting first-half profit and revenue that trailed forecasts.
Best Healthcare Technology Companies To Invest In 2014: Agenus Inc.(AGEN)
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. It offers Oncophage vaccine for the treatment of adjuvant renal cell carcinoma. The company?s products under development include Prophage series of cancer vaccines, which has been tested in Phase III clinical trials for the treatment of renal cell carcinoma (RCC) and metastatic melanoma, as well as has been tested in Phase I and Phase II clinical trials in various indications; and under Phase II clinical trials in glioma, a type of brain cancer, and adjuvant renal cell carcinoma. The Prophage series of cancer vaccines include R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its product candidate portfolio includes QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer, melanoma, malaria, and shingles, as well as in for the treatment of va rious infectious diseases and Alzheimer?s disease; and HerpV that completed Phase 1 clinical trial for the treatment of genital herpes. The company was formerly known as Antigenics Inc. and changed its name Agenus Inc. in January 2011 to reflect its existing product pipeline. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Advisors' Opinion:- [By John Udovich] Follow-on Stock Offerings From Small Cap Biotech Stocks. Thanks to the boom in biotech IPOs along with the sector�� overall performance, already listed biotechs have the option to ask investors for more cash in the form of a follow-on offering. Recently, FierceBiotech.com noted how four small cap biotechs raised $276 million from follow-on offerings in just one day last week. These small caps�included Epizyme Inc (NASDAQ: EPZM) which raised $88 million, Halozyme Therapeutics, Inc (NASDAQ: HALO) which raised $100 million, Agenus Inc (NASDAQ: AGEN) which raised $52 million and Idera Pharmaceuticals Inc (NASDAQ: IDRA) which raised $36 million. FierceBiotech.com noted that the�steady flow of about $4.5 billion a year in venture cash�along with�more than $3.5 billion from IPOs last year plus all of the�follow-ons are helping to foster both company growth and�accelerate drug�development programs. Mixed Bag for Biotech IPOs. Last Wednesday also saw two small cap biotech IPOs fizzle in one day�with small cap T cell vaccine developer�Genocea Biosciences Inc (NASDAQ: GNCA) raising $60 million but then ending the day down 8.3% to close at $11 while Dutch drug developer uniQure NV (QURE) raised $81.9 million but fell more than 14% to $14.61. However, orphan drug stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX), which is developing�drugs to treat orphan diseases like Tourette syndrome, saw a 30.5% gain to close at $15.66 and raise $84 million. The Boston Globe quoted Michael Ringel, a partner and managing director at Boston Consulting Group who focuses on health care business, as saying:
��he mood is incredibly positive. Capital is flowing. [The biotech IPOs]��have been burning hot. I think it�� too early to suggest that is changing. I can�� predict the overall economy any better than anyone else, but I would expect a pretty good year for IPOs.��/p>
No comments:
Post a Comment